Mark Avagliano
2020
In 2020, Mark Avagliano earned a total compensation of $1.4M as Chief Business Officer at G1 Therapeutics, a 74% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $151,200 |
|---|---|
| Option Awards | $837,165 |
| Salary | $431,417 |
| Other | $18,445 |
| Total | $1,438,227 |
Avagliano received $837.2K in option awards, accounting for 58% of the total pay in 2020.
Avagliano also received $151.2K in non-equity incentive plan, $431.4K in salary and $18.4K in other compensation.
Rankings
In 2020, Mark Avagliano's compensation ranked 7,018th out of 13,090 executives tracked by ExecPay. In other words, Avagliano earned more than 46.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,018 out of 13,090 | 46th |
Division Manufacturing | 2,929 out of 5,621 | 48th |
Major group Chemicals And Allied Products | 1,182 out of 2,254 | 48th |
Industry group Drugs | 1,016 out of 1,954 | 48th |
Industry Pharmaceutical Preparations | 756 out of 1,459 | 48th |
Source: SEC filing on April 28, 2021.
Avagliano's colleagues
We found five more compensation records of executives who worked with Mark Avagliano at G1 Therapeutics in 2020.